[{"id":"55f18542-ba64-4815-a6b2-b0e8baf568b2","acronym":"","url":"https://clinicaltrials.gov/study/NCT04196530","created_at":"2021-01-18T20:27:08.705Z","updated_at":"2024-07-02T16:35:08.344Z","phase":"Phase 1","brief_title":"BDB001-102: Open Label Dose Escalation of BDB001 in Combination w Atezolizumab","source_id_and_acronym":"NCT04196530","lead_sponsor":"Eikon Therapeutics","biomarkers":" CTLA4 • IL2 • TNFRSF9","pipe":"","alterations":" ","tags":["CTLA4 • IL2 • TNFRSF9"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Tecentriq (atezolizumab) • resiquimod sulfate (EIK1001)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 40","initiation":"Initiation: 11/21/2019","start_date":" 11/21/2019","primary_txt":" Primary completion: 07/01/2024","primary_completion_date":" 07/01/2024","study_txt":" Completion: 07/01/2024","study_completion_date":" 07/01/2024","last_update_posted":"2024-04-22"}]